A recent report by the Pediatric Eye Disease Investigators Group (PEDIG) provides evidence that increasing patching from two to six hours a day is effective at treating persistent amblyopia. The research was funded by the National Eye Institute, a part of the National Institutes of Health.
Some of the most common vision disorders take their toll by damaging blood vessels near the retina. But it’s difficult for eye care professionals and researchers to see these vessels with standard techniques. NIH’s National Eye Institute is supporting the development of new methods to get deeper, more detailed views of the retinal vasculature.
November is National Diabetes Month. It's a good time to remember that people with diabetes are at risk for vision loss from diabetic eye disease. Anyone with diabetes should have a comprehensive dilated eye exam at least once a year.
Ten years after a transplant, a cornea from a 71-year-old donor is likely to remain as healthy as a cornea from a donor half that age, according to a study funded by the National Institutes of Health. Corneas from donors over age 71 perform slightly less well, but still remain healthy for the majority of transplant recipients after 10 years, the study found.
Small research labs provide an engine of discovery for new therapies. But developing a new drug or device requires expertise that is typically beyond the scope of a single lab. NEI has a program that helps diverse experts work together and move potential therapies into clinical trials.
Glaucoma is a stealthy disease. It can cause irreparable damage to the eyes before there is any vision loss. It also has been known since antiquity, but its cause is a mystery in most cases. Glaucoma Awareness Month is a good time to ask: Are researchers making progress toward solving this mystery?
For adults and children who undergo cataract surgery, implantation of an artificial lens is the standard of care. But a clinical trial suggests that for most infants, surgery followed by the use of contact lenses for several years—and an eventual lens implant—may be the better solution.
An inexpensive glaucoma drug, when added to a weight loss plan, can improve vision for women with idiopathic intracranial hypertension (IIH), according to a study funded by NEI. This disorder mostly affects young, overweight women. Vision loss and headaches are common symptoms.
A new study offers an explanation for how years of chronic sunlight exposure can increase the risk of cataract, a clouding of the eye lens that typically occurs with aging. The study firms up a link between the sun’s damaging rays and a process called oxidative stress.
In laboratory tests, researchers have used electrical stimulation of retinal cells to produce the same patterns of activity that occur when the retina sees a moving object. Although more work remains, this is a step toward restoring natural, high-fidelity vision to blind people.
Telemedicine is an effective strategy to screen for the potentially blinding disease known as retinopathy of prematurity (ROP), according to a study funded by the National Eye Institute (NEI). The investigators say that the approach, if adopted broadly, could help ease the strain on hospitals with limited access to ophthalmologists and lead to better care for infants in underserved areas of the country. NEI is a part of the National Institutes of Health.
Uveitis occurs when immune cells invade the eye, causing inflammation, swelling and vision loss. Researchers at the National Eye Institute (NEI) have found a unique type of immune cell and a secreted protein that, in tests on mice, can protect against the disease.
Researchers at the National Eye Institute (NEI) have described the functions of a gene responsible for anchoring cilia – sensory hair-like extensions present on almost every cell of the body. They show in a mouse model that without the gene Cc2d2a, cilia throughout the body failed to grow, and the mice died during the embryonic stage. The finding adds to an expanding body of knowledge about ciliopathies, a class of genetic disorders that result from defects in the structure or function of cilia.
Depression is a common risk for people who have lost their vision from age-related macular degeneration (AMD), but a new study shows that a type of rehabilitation therapy can cut this risk in half.
Researchers at the National Institutes of Health have developed a technique that will speed up the production of stem-cell derived tissues. The technique will help the researchers in their efforts to use patients’ skin cells to regenerate retinal pigment epithelium (RPE)—a tissue in the back of the eye that is affected in several blinding eye diseases. It will also help the scientists search for drugs for personalized treatments.
National Eye Institute funded researchers launch an FDA-approved Phase I clinical trial to test the safety and efficacy of a novel drug called P-321 Ophthalmic Solution. The drug is applied as an eye drop and targets a unique mechanism involved in maintaining moisture in the eye.
In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or worse at the start of the trial. However, the three drugs resulted in similar average improvement when starting vision was 20/40 to 20/32. Investigators found no major differences in the safety of the three drugs. The trial was funded by the National Eye Institute (NEI), part of the National Institutes of Health.
Five bold projects will develop new technology to noninvasively image cells of the eye in unprecedented detail. The National Eye Institute (NEI) announced the awards as part of its Audacious Goals Initiative. NEI has committed $3.8 million to the projects in 2015 and up to $17.9 million over the next five years, pending the availability of funds. NEI is part of the National Institutes of Health.
Leber congenital amaurosis (LCA) is an inherited disorder that causes vision loss starting in childhood. This is the latest report from an ongoing clinical trial of gene therapy for the disorder, funded by the National Eye Institute (NEI), part of the National Institutes of Health.
Much like the automatic focus of a camera, our eyes and brains must constantly recalibrate so that we can get a clear view of the changing—and always moving—world around us. Two studies funded by the National Eye Institute (NEI) show how the circuitry for this eye-brain coordination is assembled during early embryonic development.
Spider-like cells inside the brain, spinal cord and eye hunt for invaders, capturing and then devouring them. These cells, called microglia, often play a beneficial role by helping to clear trash and protect the central nervous system against infection. But a new study by researchers at the National Eye Institute (NEI) shows that they also accelerate damage wrought by blinding eye disorders, such as retinitis pigmentosa. NEI is part of the National Institutes of Health.
Children who sleep in unventilated rooms with cooking fires are at greater risk for severe trachoma, a leading cause of preventable blindness in developing countries, according to the findings of a recent study conducted in Tanzania. The study was supported by the National Eye Institute, part of the National Institutes of Health.
The inflammatory eye disorder autoimmune uveitis occurs when a person’s immune system goes awry, attacking proteins in the eye. What spurs this response is a mystery, but now a National Eye Institute study on mice suggests that bacteria in the gut may provide a kind of training ground for immune cells to attack the eye.
While some research suggests that a diet high in omega-3 fatty acids can protect brain health, a large clinical trial by researchers at the National Institutes of Health found that omega-3 supplements did not slow cognitive decline in older persons. With 4,000 patients followed over a five-year period, the study is one of the largest and longest of its kind. It was published today in the Journal of the American Medical Association.
When we move our head, the whole visual world moves across our eyes. Yet we can still make out a bee buzzing by or a hawk flying overhead, thanks to unique cells in the eye called object motion sensors. A new study on mice helps explain how these cells do their job, and may bring scientists closer to understanding how complex circuits are formed throughout the nervous system. The study was funded by the National Institutes of Health, and was published online in Nature.
Following the 2014 Ebola outbreak in West Africa that took the lives of more than 11,200 people in the region, the National Eye Institute, part of the National Institutes of Health, has deployed a team of clinicians and technical experts to Monrovia, Liberia to investigate the long-term effects of Ebola on the eye.
People with a genetic predisposition for age-related macular degeneration (AMD) significantly increased their odds of developing the blinding eye disorder if they had a history of heavy smoking and consistently did not exercise or eat enough fruits and vegetables, according to an observational study of women funded by the National Eye Institute, part of the National Institutes of Health.
Researchers funded by the National Institutes of Health have developed a novel mouse model for the vision disorder Leber hereditary optic neuropathy (LHON), and found that they can use gene therapy to improve visual function in the mice. LHON is one of many diseases tied to gene mutations that damage the tiny energy factories that power our cells, called mitochondria.
The National Eye Institute (NEI), part of NIH, has appointed three new members to the National Advisory Eye Council (NAEC) who are attending their first NAEC meeting as council members today. The NAEC provides guidance on research, training, and other NEI programs.
Gene therapy preserved vision in a study involving dogs with naturally occurring, late-stage retinitis pigmentosa, according to research funded by the National Eye Institute (NEI), part of the National Institutes of Health. The findings contribute to the groundwork needed to move gene therapy forward into clinical trials for people with the blinding eye disorder, for which there is currently no cure.
A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy. The trial, conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) compared Lucentis with a type of laser therapy called panretinal or scatter photocoagulation, which has remained the gold standard for proliferative diabetic retinopathy since the mid-1970s. The findings demonstrate the first major therapy advance in nearly 40 years.
This National Diabetes Month, there is some good news for people with eye complications from diabetes. Earlier this month, a network of researchers supported by the National Eye Institute (NEI) found that the drug Lucentis (ranibizumab) can be highly effective for treating proliferative diabetic retinopathy, an eye disease that can occur as a complication of diabetes. The researchers, part of the Diabetic Retinopathy Clinical Research Network, say this is the first major advance in therapy in 40 years.
Another reason to worry about climate change: Expanding areas of arid land, air pollution, and greater exposure to ultraviolet (UV) radiation all present potential health hazards to your eyes, according to Sheila West, Ph.D., vice chair for research at the Wilmer Eye Institute, Johns Hopkins University. In October, West discussed these hazards at a symposium on the health consequences of climate change.
An international study of about 43,000 people has significantly expanded the number of genetic factors known to play a role in age-related macular degeneration (AMD), a leading cause of vision loss among people age 50 and older. Supported by the National Eye Institute (NEI), part of the National Institutes of Health, the findings may help improve our understanding of the biological processes that lead to AMD and identify new therapeutic targets for potential drug development.
As we age, proteins in the lenses of our eyes start misbehaving: They unfold and congregate in clusters that block, scatter and distort light as it passes through the lens. A cloudy area, or cataract, forms. In a new study, scientists found that throughout our lifetime, levels of a key protein decline, and may be an early warning sign of a developing cataract. The study, conducted by scientists at the National Eye Institute and the Wilmer Eye Institute of Johns Hopkins Hospital and published online in Ophthalmology, suggests that there is a window before cataracts develop when there may be time to intervene and prevent them.
Our eyes are especially demanding when it comes to energy: Along with our brain, they require a substantial amount of power to keep them functioning and healthy. Now a new study by the National Eye Institute suggests that because of their high-energy demands, our eyes function at high efficiency and with little reserve capacity, which scientists say may explain why they become vulnerable to degenerative diseases.
An analysis funded by the National Eye Institute (NEI), part of the National Institutes of Health, has identified three genes that contribute to the most common type of glaucoma. The study increases the total number of such genes to 15.
A study funded by the National Eye Institute (NEI), part of the National Institutes of Health, has shown that uncorrected farsightedness (hyperopia) in preschool children is associated with significantly worse performance on a test of early literacy.
A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab), but only among participants starting treatment with 20/50 or worse vision. Gains after two years were about the same for Eylea and Lucentis (ranibizumab), contrary to year-one results from the study, which showed Eylea with a clear advantage. The three drugs yielded similar gains in vision for patients with 20/32 or 20/40 vision at the start of treatment. The clinical trial was conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net), which is funded by the National Eye Institute, part of the National Institutes of Health.
Andrew Butler may be one of the hardest working people at the National Institutes of Health. Not even Winter Storm Jonas could keep him away. After the blizzard struck the East Coast in late January, the NIH campus in Bethesda, Maryland was buried in snow and eerily quiet for several days. Still, Butler reported for all of his daily shifts except one, when his supervisors asked him to stay home. Butler’s dedication is important, because he works at the Building 49 Central Animal Facility—home to the many rodents and other laboratory animals that are a vital part of NIH research—helping ensure that they receive the care they need.
Making the most of the low light in the muddy rivers where it swims, the elephant nose fish survives by being able to spot predators amongst the muck with a uniquely shaped retina, the part of the eye that captures light. In a new study, researchers looked to the fish’s retinal structure to inform the design of a contact lens that can adjust its focus.
Feature story with patient perspective emphasizes the importance of having a comprehensive dilated eye exam, which is the best way to find out for sure if eyes are healthy.
In a study of nearly 650 people with the eye disease age-related macular degeneration (AMD), half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with anti-VEGF drugs that are injected into the eye. The authors of the study, funded by the National Eye Institute (NEI) at the National Institutes of Health, say those outcomes would have been unimaginable about 10 years ago, prior to the drugs' availability.
In a study of nearly 650 people with the eye disease age-related macular degeneration (AMD), half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with anti-VEGF drugs that are injected into the eye. The authors of the study, funded by the National Eye Institute (NEI) at the National Institutes of Health, say those outcomes would have been unimaginable about 10 years ago, prior to the drugs' availability.
The number of people with visual impairment or blindness in the United States is expected to double to more than 8 million by 2050, according to projections based on the most recent census data and from studies funded by the National Eye Institute, part of the National Institutes of Health. Another 16.4 million Americans are expected to have difficulty seeing due to correctable refractive errors that can be fixed with glasses, contacts or surgery.
People with type 2 diabetes who intensively controlled their blood sugar level during the landmark ACCORD Trial Eye Study were found to have cut their risk of diabetic retinopathy in half in a follow-up analysis conducted four years after stopping intensive therapy. Investigators who led the ACCORD Follow-on Eye Study (ACCORDION) announced the results today in New Orleans at the American Diabetes Association annual meeting. The study was supported by the National Eye Institute.
A new study led by researchers the National Eye Institute suggests how the genesis of rod photoreceptors may have occurred to give rise to nocturnal mammals.
A study in mice funded by the National Institutes of Health (NIH) shows for the first time that high-contrast visual stimulation can help damaged retinal neurons regrow optic nerve fibers, otherwise known as retinal ganglion cell axons. In combination with chemically induced neural stimulation, axons grew further than in strategies tried previously. Treated mice partially regained visual function. The study also demonstrates that adult regenerated central nervous system (CNS) axons are capable of navigating to correct targets in the brain. The research was funded through the National Eye Institute (NEI), a part of NIH.
Combinations of Food and Drug Administration-approved drugs protect against the loss of cells required for vision in a mouse model of the damage caused by blinding retinal diseases.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right